Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10966286 | Vaccine | 2013 | 5 Pages |
Abstract
The Bacille Calmette-Guérin (BCG) vaccine is the only vaccine currently available for tuberculosis, and it demonstrates variable efficacy against the disease. The assessment of new vaccine strategies is hindered by the small annual probability that an infected individual will develop tuberculosis, and the lack of simple and reliable surrogate markers of protection. The frequency of cytokine-producing T cells as well as the production of IFN-γ have been disputed as surrogate markers of protection. We evaluated the evolution of these immune parameters in a population from a high burden city where BCG revaccination has been shown to result in mild protection. We found that individuals whose in vitro IFN-γ responses to mycobacterial antigens had increased by more than 3.3-fold were more likely to maintain higher responses after 1 year and to show increased expansion of IFN-γ-producing T lymphocytes than those with lower or null increase of IFN-γ.
Keywords
IFN-γTNFMTBPPDTSTPhytohemagglutininBCGROCPHAPBMCTuberculin skin testVaccine evaluationinterferon-gammainterleukinTuberculosisHuman populationsperipheral blood mononuclear cellstumor necrosis factor.confidence intervalCorrelates of protectionTuberculosis vaccinesHIVhuman immunodeficiency virusreceiver operating characteristic
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Evelin S. Oliveira, Jamocyr M. Marinho, Theolis Barbosa, for the study group for the study group,